A Phase 1 Study of AJ1-11095 in People With Myelofibrosis

Full Title

A Multicenter, Open-Label, Phase 1 Study of AJ1-11095 Administered as Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Purpose

Researchers want to find the best dose of AJ1-11095 to treat myelofibrosis. The people in this study have myelofibrosis that came back or got worse after treatment.

AJ1-11095 works by blocking JAK proteins. When JAK proteins send too many signals, the body makes the wrong amount of blood cells. By blocking these proteins, AJ1-11095 may slow JAK signaling and help your body make the right amount of blood cells. AJ1-11095 is taken orally (by mouth).

Contact

For more information and to see if you can join this study, please call Dr. Raajit Rampal’s office at 646-608-3746.